Dupilumab associated with highly favorable outcomes in Type 2 Chronic Rhinosinusitis

Switzerland: A recent study published in Allergy, European Journal of Allergy and Clinical Immunology, predicted treatment outcome as "highly favorable" after one-week treatment of Type 2 Chronic...

Related Keywords

Zurich ,Züsz ,Switzerland ,Danielle Fehr ,Peter Schmid Grendelmeier ,Michaelb Soyka ,Rhinosinusitis Michaelb Soyka ,Ursc Steiner ,Fabios Ryser ,Regeneron Pharmaceuticals ,University Hospital ,University Hospital Zurich ,Drug Administration ,Department Of Immunology At University ,Department Of Otorhinolaryngology At Head ,Neck Surgery University ,European Journal ,Clinical Immunology ,Dupilumab Treatment Outcome ,Rhinosinusitis Michael ,Allergy ,Chronic Rhinosinusitis ,Nasal Polyps ,Dupilumab ,Pg ,Ype 2 Inflammatory Pattern ,Sinuses ,Polyps ,